Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.
DiNardo, Courtney D; Stein, Eytan M; de Botton, Stéphane; Roboz, Gail J; Altman, Jessica K; Mims, Alice S; Swords, Ronan; Collins, Robert H; Mannis, Gabriel N; Pollyea, Daniel A; Donnellan, Will; Fathi, Amir T; Pigneux, Arnaud; Erba, Harry P; Prince, Gabrielle T; Stein, Anthony S; Uy, Geoffrey L; Foran, James M; Traer, Elie; Stuart, Robert K; Arellano, Martha L; Slack, James L; Sekeres, Mikkael A; Willekens, Christophe; Choe, Sung; Wang, Hongfang; Zhang, Vickie; Yen, Katharine E; Kapsalis, Stephanie M; Yang, Hua; Dai, David; Fan, Bin; Goldwasser, Meredith; Liu, Hua; Agresta, Sam; Wu, Bin; Attar, Eyal C; Tallman, Martin S; Stone, Richard M; Kantarjian, Hagop M.
N Engl J Med
; 378(25): 2386-2398, 2018 Jun 21.
Artigo em Inglês | MEDLINE | ID: mdl-29860938
Exposure-safety-efficacy analysis of single-agent ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma: dose selection for a phase 3 maintenance study.
Phase II study of tosedostat with cytarabine or decitabine in newly diagnosed older patients with acute myeloid leukaemia or high-risk MDS.
Guanidinoacetic acid as a performance-enhancing agent.
Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes.
A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis.
A Phase Ib dose-escalation study to evaluate safety and tolerability of the addition of the aminopeptidase inhibitor tosedostat (CHR-2797) to paclitaxel in patients with advanced solid tumours.
Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients.
Advanced physiological roles of guanidinoacetic acid.
Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy.
Synthesis and structure activity relationships of glycine amide derivatives as novel Vascular Adhesion Protein-1 inhibitors.